RecruitingAutoimmune DiseasesRheumatoid Arthritis (RA)Psoriatic Arthritis (PsA)

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

Eligible age

18–75 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in adults with autoimmune or immune-mediated disease including rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), cutaneous lupus erythematosus (CLE) with or without systemic manifestations, or atopic dermatitis (AD).

Sponsor: Seismic Therapeutic AU Pty Ltd

Source: ClinicalTrials.gov · NCT07455578 · last updated 2026-06-01